ADMA Biologics Inc (ADMA)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 139,332 | 115,242 | 84,289 | 44,615 | 21,632 | 1,340 | -16,662 | -25,364 | -39,366 | -46,498 | -51,618 | -58,024 | -58,373 | -62,402 | -61,766 | -63,309 | -64,915 | -55,522 | -50,771 | -44,986 |
| Long-term debt | US$ in thousands | 72,337 | 101,326 | 131,074 | 130,847 | 130,594 | 142,026 | 140,312 | 144,301 | 142,833 | 141,366 | 139,811 | 138,423 | 94,866 | 94,363 | 93,877 | 93,413 | 92,969 | 97,044 | 96,574 | 96,129 |
| Total stockholders’ equity | US$ in thousands | 349,018 | 231,890 | 188,269 | 153,706 | 135,206 | 151,437 | 146,762 | 145,655 | 151,974 | 100,385 | 114,401 | 126,933 | 141,173 | 102,780 | 111,594 | 112,504 | 88,249 | 71,376 | 76,879 | 96,336 |
| Return on total capital | 33.07% | 34.58% | 26.39% | 15.68% | 8.14% | 0.46% | -5.80% | -8.75% | -13.35% | -19.23% | -20.31% | -21.87% | -24.73% | -31.65% | -30.06% | -30.74% | -35.82% | -32.97% | -29.27% | -23.37% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $139,332K ÷ ($72,337K + $349,018K)
= 33.07%
Over the analyzed period from March 31, 2020, to December 31, 2024, ADMA Biologics Inc's return on total capital has shown a fluctuating trend. The company started with negative returns on total capital reaching as low as -35.82% by December 31, 2020.
However, the company's performance gradually improved, with the return on total capital moving to -8.75% by March 31, 2023, turning positive at 0.46% by September 30, 2023.
The positive trend continued, with the return on total capital increasing significantly to 33.07% by December 31, 2024. This suggests that ADMA Biologics Inc has been able to effectively utilize its total capital to generate returns for its stakeholders as it managed to turn around from negative returns to positive and achieved a substantial return on total capital by the end of the period.
Peer comparison
Dec 31, 2024